We Have Better Obesity Medications, but Access Is Lagging
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
Diagnosis & Disease Information
Maker of Weight-Loss Drug Wegovy Ramps Up Production to Meet Demand
The company expects ‘pent-up demand’ for the Wegovy (semaglutide) to subside within the next few months
More Support and Critique of AAP Guideline for Childhood Obesity
Two more medical societies have come out in support of the AAP’s updated clinical guidelines for obesity treatment in children and adolescents and one opposes it.
Obesity Organizations Release Consensus Statement
Six organizations that focus on the diagnosis and treatment of obesity have released a consensus statement to reduce barriers to care.
Wegovy Gains Approval for Treating Obesity in Adolescents
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Semaglutide Reduces BMI More Than Lifestyle Changes in Teens With Obesity
Semaglutide is a glucagon-like peptide-1 receptor agonist.
Effects of Weight Loss Methods Examined by Baseline Body Weight
Unlike people with obesity, lean individuals may not experience health benefits with intentional weight loss.
Marked Weight Loss Found in Assisted Living Residents During Quarantine
Nearly half of patients at assisted living facilities showed significant weight loss early during the COVID-19 pandemic.
Guideline for Preventing Weight Gain in Women at Midlife
Panel recommends counseling all women aged 40 to 60 years on healthy eating and physical activity to maintain weight or prevent weight gain.
Weight-Loss Program Based on the 5As Framework Shows Success in College Students
Effective weight-management resources were delivered to more than 75% of college students with a high BMI within 90 days.
- Loading...
Loading...
Next post in AANP 2022
Loading... 
Loading...